Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

Auteurs : El Hachem G, Gombos A, Awada A
Jaar : 2021
Journal : Expert Rev Anticancer Ther
Volume : 21
Pagina's : 81-92